FDA Expert Panel 2025/2026 — Labeling Evolution
Following a landmark expert panel in July 2025, the FDA enters 2026 with a more granular approach to hormone labeling. While "Black Box" warnings still exist for the category, the agency is now distinguishing between delivery methods.
Route of Administration Matters: In 2026, the FDA acknowledged that transdermal delivery (patches and gels) carries a statistically lower risk of blood clots and stroke than oral synthetic hormones because they bypass the liver's "first-pass" metabolism.
Public Docket Insights: The FDA’s 2026 focus is on "Formulation-Specific Safety." This means labels are becoming more specific to the molecule rather than the class, recognizing that a bioidentical molecule may have different metabolic pathways than its synthetic cousins.